search
Back to results

Environmental Control as Add-on Therapy in Childhood Asthma (ECATCh)

Primary Purpose

Asthma

Status
Completed
Phase
Phase 2
Locations
United States
Study Type
Interventional
Intervention
Flovent Diskus
Home Environmental Intervention
Advair Diskus
Sponsored by
Johns Hopkins University
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Asthma

Eligibility Criteria

5 Years - 17 Years (Child)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Have physician-diagnosed asthma at least 1 year prior to the baseline visit, or asthma symptoms for at least 1 year
  • Meet criteria for current persistent asthma defined as either:

    1. On a long-term controller medication for asthma, or
    2. Meet National Asthma Education and Prevention Program (NAEPP) guideline requirements for persistent disease:(46)
  • Asthma symptoms 3 or more days per week over the past 2 weeks or
  • Nocturnal asthma symptoms at least 3 times in the past month
  • Have evidence of uncontrolled disease as defined by at least one of the following:

    1. One asthma-related unscheduled visit to an emergency department (ED), clinic or urgent care facility in the previous 12 mo
    2. One asthma-related overnight hospitalization in the previous 12 mo
    3. One or more bursts of oral corticosteroids in the previous 12 mo
  • Reside within a geographic area of the study site so that home visits are feasible.
  • Have no plans to move within the upcoming 6 months
  • Have insurance to cover prescription medications.
  • Have a positive skin test (net wheal ≥2mm) to cat, dog, mouse, cockroach, or dust mites or have a positive cat, dog, mouse, German cockroach, or D. farinae-specific immunoglobulin E (IgE) test, as quantified using the ImmunoCAP system (≥0.35 kU/L)

Exclusion Criteria:

  • Lung disease, other than asthma, that requires daily medication
  • Cardiovascular disease that requires daily medication, excluding hypertension
  • Taking a beta-blocker
  • Allergy to dairy
  • On Xolair < 5 months
  • On immunotherapy and has not reached maintenance dose
  • Sleeping in another home 4 or more nights/week
  • Active smoker defined as a positive urine screen for high levels of urine cotinine
  • Unable to access areas of home necessary to conduct extermination

Sites / Locations

  • Johns Hopkins University

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

ECS + Medication Group

Medication Group Alone

Arm Description

The Environmental Control Strategy ("Home Environmental Intervention") plus inhaled corticosteroids or inhaled corticosteroids plus long-acting beta agonist. (Flovent Diskus or Advair diskus)

inhaled corticosteroids or inhaled corticosteroids plus long-acting beta agonist. (Flovent Diskus or Advair diskus)

Outcomes

Primary Outcome Measures

The Medication Treatment Step Assigned
The controller medication treatment step that was assigned at the visit, which is based on the current controller medication treatment step and the current level of asthma control. The range is from 0-6, with 0 indicating no controller medication and 6 indicating high dose inhaled corticosteroids plus long-acting beta agonist.

Secondary Outcome Measures

Daily Inhaled Corticosteroid Dose
micrograms of inhaled corticosteroids (daily)
Exhaled Nitric Oxide
Exhaled nitric oxide in parts per billion.
Number of Asthma Symptom Days
Number of asthma symptom days in the past two weeks will be a measure of asthma control.
Number of Asthma Exacerbations
Asthma exacerbations will be assessed by number of acute visits to the emergency department (ED), hospitalizations and urgent doctor visits.
FEV1/FVC
Forced expiratory volume at one second/forced vital capacity (FEV1/FVC) will be evaluated as a continuous variable. This is a ratio without any units.

Full Information

First Posted
September 22, 2014
Last Updated
November 8, 2019
Sponsor
Johns Hopkins University
search

1. Study Identification

Unique Protocol Identification Number
NCT02251379
Brief Title
Environmental Control as Add-on Therapy in Childhood Asthma
Acronym
ECATCh
Official Title
Environmental Control as Add-on Therapy in Childhood Asthma
Study Type
Interventional

2. Study Status

Record Verification Date
November 2019
Overall Recruitment Status
Completed
Study Start Date
October 1, 2014 (Actual)
Primary Completion Date
November 2018 (Actual)
Study Completion Date
November 2018 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Johns Hopkins University

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
This study evaluates the effects of adding on an environmental home intervention to standard asthma medication management on controller medication requirements among children and adolescents with asthma. The investigators hypothesize that the addition of an individually-tailored, multi-faceted Environmental Control Strategy (ECS) to guidelines-based controller medication will result in less controller medication requirement and allergic inflammation than controller medication alone among urban asthmatic children.
Detailed Description
The study is a parallel arm study of an individually tailored, multi-faceted ECS plus controller medication titration versus controller medication titration alone. After a 4-week run-in period to stabilize the asthma, the investigators will randomize 200 Baltimore children with persistent asthma and a recent exacerbation in a 1:1 ratio to the two arms and follow the children for six months. There will be five clinic visits and three home visits over this time period for clinical and home assessments, respectively. There will be up to four environmental intervention visits for participants randomized to the environmental control plus controller medication group. The environmental modules include mouse, cockroach, furry pets, dust mites, and smoking. Air purifiers and laundered bedding are also included in this arm. Participants randomized to the controller medication group have the option of having one home visit after completing the study at which the participants will receive home intervention services that the environmental control plus controller medication group received. Participants will have repeated assessment of: controller medication requirements; secondary clinical, physiologic, and inflammatory outcomes; and particulate matter (PM), air nicotine, and allergen levels.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Asthma

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
155 (Actual)

8. Arms, Groups, and Interventions

Arm Title
ECS + Medication Group
Arm Type
Experimental
Arm Description
The Environmental Control Strategy ("Home Environmental Intervention") plus inhaled corticosteroids or inhaled corticosteroids plus long-acting beta agonist. (Flovent Diskus or Advair diskus)
Arm Title
Medication Group Alone
Arm Type
Active Comparator
Arm Description
inhaled corticosteroids or inhaled corticosteroids plus long-acting beta agonist. (Flovent Diskus or Advair diskus)
Intervention Type
Drug
Intervention Name(s)
Flovent Diskus
Other Intervention Name(s)
Flovent Diskus, 50 mcg, 100mcg, 250 mcg
Intervention Description
Inhaled corticosteroids
Intervention Type
Other
Intervention Name(s)
Home Environmental Intervention
Intervention Description
Mouse, Cockroach, Furry pets, Dust mites, Smoking, air purifiers, laundered bedding
Intervention Type
Drug
Intervention Name(s)
Advair Diskus
Intervention Description
inhaled corticosteroids + long-acting beta agonist
Primary Outcome Measure Information:
Title
The Medication Treatment Step Assigned
Description
The controller medication treatment step that was assigned at the visit, which is based on the current controller medication treatment step and the current level of asthma control. The range is from 0-6, with 0 indicating no controller medication and 6 indicating high dose inhaled corticosteroids plus long-acting beta agonist.
Time Frame
6 month clinic visit
Secondary Outcome Measure Information:
Title
Daily Inhaled Corticosteroid Dose
Description
micrograms of inhaled corticosteroids (daily)
Time Frame
6 months
Title
Exhaled Nitric Oxide
Description
Exhaled nitric oxide in parts per billion.
Time Frame
6 months
Title
Number of Asthma Symptom Days
Description
Number of asthma symptom days in the past two weeks will be a measure of asthma control.
Time Frame
6 months
Title
Number of Asthma Exacerbations
Description
Asthma exacerbations will be assessed by number of acute visits to the emergency department (ED), hospitalizations and urgent doctor visits.
Time Frame
6 months
Title
FEV1/FVC
Description
Forced expiratory volume at one second/forced vital capacity (FEV1/FVC) will be evaluated as a continuous variable. This is a ratio without any units.
Time Frame
6 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
5 Years
Maximum Age & Unit of Time
17 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Have physician-diagnosed asthma at least 1 year prior to the baseline visit, or asthma symptoms for at least 1 year Meet criteria for current persistent asthma defined as either: On a long-term controller medication for asthma, or Meet National Asthma Education and Prevention Program (NAEPP) guideline requirements for persistent disease:(46) Asthma symptoms 3 or more days per week over the past 2 weeks or Nocturnal asthma symptoms at least 3 times in the past month Have evidence of uncontrolled disease as defined by at least one of the following: One asthma-related unscheduled visit to an emergency department (ED), clinic or urgent care facility in the previous 12 mo One asthma-related overnight hospitalization in the previous 12 mo One or more bursts of oral corticosteroids in the previous 12 mo Reside within a geographic area of the study site so that home visits are feasible. Have no plans to move within the upcoming 6 months Have insurance to cover prescription medications. Have a positive skin test (net wheal ≥2mm) to cat, dog, mouse, cockroach, or dust mites or have a positive cat, dog, mouse, German cockroach, or D. farinae-specific immunoglobulin E (IgE) test, as quantified using the ImmunoCAP system (≥0.35 kU/L) Exclusion Criteria: Lung disease, other than asthma, that requires daily medication Cardiovascular disease that requires daily medication, excluding hypertension Taking a beta-blocker Allergy to dairy On Xolair < 5 months On immunotherapy and has not reached maintenance dose Sleeping in another home 4 or more nights/week Active smoker defined as a positive urine screen for high levels of urine cotinine Unable to access areas of home necessary to conduct extermination
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Elizabeth C Matsui, MD MHS
Organizational Affiliation
Johns Hopkins University
Official's Role
Study Chair
First Name & Middle Initial & Last Name & Degree
Meredith McCormack, MD MHS
Organizational Affiliation
Johns Hopkins University
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Corinne Keet, MD PHD
Organizational Affiliation
Johns Hopkins University
Official's Role
Principal Investigator
Facility Information:
Facility Name
Johns Hopkins University
City
Baltimore
State/Province
Maryland
ZIP/Postal Code
21287
Country
United States

12. IPD Sharing Statement

Learn more about this trial

Environmental Control as Add-on Therapy in Childhood Asthma

We'll reach out to this number within 24 hrs